Clinical trial
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men
NCT00287833 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00287833 |
|---|---|
| Title | Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men |
| Official title | Phase I Single Dose Safety and Pharmacokinetic Study of Bowman Birk Inhibitor Concentrate, Delivered as an Orange Juice Suspension to Healthy Male Volunteers Between 18 and 65 Years of Age |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | placebo, Bowman-Birk inhibitor concentrate |
| Enrollment | 20 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2007 |
| First posted | Feb 7, 2006 |
| Last update posted | May 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: